Cidara Therapeutics Inc
CDTX62.905USD
+0.005+0.01%
시장 운영 시간 （ET）시세는 15분 지연됩니다
768.02M시가총액
손실P/E TTM
자세한 내용은 Cidara Therapeutics Inc 회사
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
회사 정보
종목 코드 CDTX
회사 이름Cidara Therapeutics Inc
상장일Apr 15, 2015
CEODr. Jeffrey L. (Jeff) Stein, Ph.D.
직원 수38
유형Ordinary Share
회계 연도 종료Apr 15
주소6310 Nancy Ridge Dr Ste 101
도시SAN DIEGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92121-3209
전화18587526170
웹사이트https://www.cidara.com/
종목 코드 CDTX
상장일Apr 15, 2015
CEODr. Jeffrey L. (Jeff) Stein, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brian Ritchie
Mr. Brian Ritchie
Investor Relations
Investor Relations
--
--
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
--
--
Mr. Shane Ward
Mr. Shane Ward
Chief Operating Officer, Chief Legal Officer, Company Secretary
Chief Operating Officer, Chief Legal Officer, Company Secretary
--
--
Dr. Josh Resnick, M.D., J.D.
Dr. Josh Resnick, M.D., J.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Chief Financial Officer
Chief Financial Officer
57.50K
--
Mr. Daniel D. (Dan) Burgess
Mr. Daniel D. (Dan) Burgess
Independent Chairman of the Board
Independent Chairman of the Board
150.00
--
Mr. Ryan Spencer
Mr. Ryan Spencer
Independent Director
Independent Director
--
--
Dr. Bonnie Bassler, Ph.D.
Dr. Bonnie Bassler, Ph.D.
Independent Director
Independent Director
--
--
Ms. Chrysa Mineo
Ms. Chrysa Mineo
Independent Director
Independent Director
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
주주
주주 유형
주주
주주
비율
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
주주
주주
비율
RA Capital Management, LP
16.69%
Commodore Capital LP
5.83%
VR Adviser, LLC
5.21%
TCG Crossover Management, LLC
4.99%
Point72 Asset Management, L.P.
4.96%
Other
62.32%
주주 유형
주주
비율
Venture Capital
29.07%
Hedge Fund
24.64%
Investment Advisor
15.03%
Investment Advisor/Hedge Fund
4.77%
Individual Investor
1.12%
Research Firm
0.52%
Pension Fund
0.12%
Other
24.73%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
130
15.18M
75.27%
+7.25M
2025Q1
124
10.47M
53.54%
+2.71M
2024Q4
122
7.70M
70.35%
+1.07M
2024Q3
109
4.49M
61.04%
+771.77K
2024Q2
109
1.90M
39.70%
+56.88K
2024Q1
108
1.55M
384.06%
-209.94K
2023Q4
111
1.70M
37.69%
-299.58K
2023Q3
119
1.90M
42.77%
-451.34K
2023Q2
126
1.95M
43.98%
-451.51K
2023Q1
153
2.02M
47.21%
-214.92K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RA Capital Management, LP
3.37M
16.69%
+2.27M
+207.97%
Jun 26, 2025
Commodore Capital LP
1.18M
5.83%
+1.18M
--
Jun 25, 2025
VR Adviser, LLC
1.05M
5.21%
+285.80K
+37.32%
Mar 31, 2025
TCG Crossover Management, LLC
1.01M
4.99%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
999.41K
4.96%
+885.56K
+777.80%
Apr 09, 2025
Adage Capital Management, L.P.
990.00K
4.91%
+620.05K
+167.60%
Mar 31, 2025
BVF Partners L.P.
924.64K
4.59%
-168.15K
-15.39%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
703.08K
3.49%
--
--
Mar 31, 2025
Canaan Partners
703.08K
3.49%
+703.08K
--
Jul 19, 2024
Vivo Capital, LLC
684.28K
3.39%
+13.68K
+2.04%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco Dorsey Wright SmallCap Momentum ETF
0.78%
iShares Micro-Cap ETF
0.15%
Avantis US Small Cap Equity ETF
0.05%
iShares Russell 2000 Value ETF
0.05%
Proshares Ultra Russell 2000
0.03%
ProShares UltraPro Russell2000
0.03%
Global X Russell 2000 ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
더 보기
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.78%
iShares Micro-Cap ETF
비율0.15%
Avantis US Small Cap Equity ETF
비율0.05%
iShares Russell 2000 Value ETF
비율0.05%
Proshares Ultra Russell 2000
비율0.03%
ProShares UltraPro Russell2000
비율0.03%
Global X Russell 2000 ETF
비율0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0.03%
ProShares Hedge Replication ETF
비율0.03%
Invesco RAFI US 1500 Small-Mid ETF
비율0.02%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
날짜
유형
비율
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
